A multiplex platform for the identification of ovarian cancer biomarkers

[1]  M. Zeegers,et al.  Multiplex screening of 422 candidate serum biomarkers in bladder cancer patients identifies syndecan-1 and macrophage colony-stimulating factor 1 as prognostic indicators , 2017 .

[2]  K. El Bairi,et al.  Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer , 2016, Cellular Oncology.

[3]  M. Kiechle,et al.  CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer , 2016, British Journal of Cancer.

[4]  K. Hasegawa,et al.  Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression , 2016, International journal of cancer.

[5]  A. Goy,et al.  The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer , 2016, Journal of Ovarian Research.

[6]  J. Mpindi,et al.  REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker , 2016, PloS one.

[7]  Jin-ping Fan,et al.  Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients , 2016, Tumor Biology.

[8]  Thomas M. Riley,et al.  PLCO: Evolution of an Epidemiologic Resource and Opportunities for Future Studies. , 2015, Reviews on recent clinical trials.

[9]  Jun Zhang,et al.  The clinical and prognostic significance of midkine in breast cancer patients , 2015, Tumor Biology.

[10]  P. Aukrust,et al.  Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation , 2015, Clinical and Translational Gastroenterology.

[11]  P. Gao,et al.  The Effect of C-X-C Motif Chemokine 13 on Hepatocellular Carcinoma Associates with Wnt Signaling , 2015, BioMed research international.

[12]  H. Brenner,et al.  Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting , 2015, Clinical Cancer Research.

[13]  Matthew Burnell,et al.  Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Oberg,et al.  Plasma immune analytes in patients with epithelial ovarian cancer. , 2015, Cytokine.

[15]  Edmond J. Breen,et al.  A novel multiplexed immunoassay identifies CEA, IL-8 and prolactin as prospective markers for Dukes’ stages A-D colorectal cancers , 2015, Clinical Proteomics.

[16]  M. Barcellos-Hoff,et al.  Development of a novel multiplexed assay for quantification of transforming growth factor-β (TGF-β) , 2015, Growth factors.

[17]  Jingyan Xie,et al.  Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy. , 2015, American journal of cancer research.

[18]  A. Sood,et al.  Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes , 2014, Journal of Ovarian Research.

[19]  L. Esserman,et al.  Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[20]  P. Hartge,et al.  Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. , 2014, Gynecologic oncology.

[21]  Shailesh Singh,et al.  Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma , 2014, International journal of oncology.

[22]  V. Kosma,et al.  Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer , 2014, BMC Cancer.

[23]  D. Jones.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases , 2014, British journal of pharmacology.

[24]  J. Gonzalez-Bosquet,et al.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress , 2014, Molecular Cancer.

[25]  I. Fournier,et al.  Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target1 , 2014, Translational oncology.

[26]  J. Stenvang,et al.  Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability , 2014, PloS one.

[27]  F. Tas,et al.  Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer , 2014, Tumor Biology.

[28]  J. Stenvang,et al.  Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals , 2013, Journal of Translational Medicine.

[29]  E. Fung,et al.  Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. , 2013, American journal of obstetrics and gynecology.

[30]  K. Partheen,et al.  Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. , 2013, Gynecologic oncology.

[31]  Richard G. Moore,et al.  A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive value , 2013, Cancer.

[32]  J. Roodenburg,et al.  FADD expression is associated with regional and distant metastasis in squamous cell carcinoma of the head and neck , 2013, Histopathology.

[33]  K. Terlikowska,et al.  Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer. , 2013, European cytokine network.

[34]  P. Oberoi,et al.  Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4 , 2013, Journal of Ovarian Research.

[35]  B. Prabhakar,et al.  Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases , 2013, Journal of Translational Medicine.

[36]  A. Chinnaiyan,et al.  Systematic, evidence-based discovery of biomarkers at the NCI , 2012, Clinical & Experimental Metastasis.

[37]  M. lenhard,et al.  Human epididymis protein 4 (HE4) in benign and malignant diseases , 2012, Clinical chemistry and laboratory medicine.

[38]  P. Validire,et al.  FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer , 2012, British Journal of Cancer.

[39]  S. Skates.  Ovarian Cancer Screening: Development of the Risk of Ovarian Cancer Algorithm (ROCA) and ROCA Screening Trials , 2012, International Journal of Gynecologic Cancer.

[40]  Richard G. Moore,et al.  Differential Diagnosis of a Pelvic Mass: Improved Algorithms and Novel Biomarkers , 2012, International Journal of Gynecologic Cancer.

[41]  R. Molina,et al.  Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. , 2011, Clinical chemistry.

[42]  R. Knapp,et al.  Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. , 2011, American journal of obstetrics and gynecology.

[43]  S. Fredriksson,et al.  Sensitive detection of cytokines in 1-μl serum samples using Proseek ® , 2011 .

[44]  Naveena Singh,et al.  Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer , 2011, Clinical Cancer Research.

[45]  Martin Lundberg,et al.  Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood , 2011, Nucleic acids research.

[46]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[47]  Sudhir Srivastava,et al.  A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer , 2011, Cancer Prevention Research.

[48]  Sudhir Srivastava,et al.  Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens , 2011, Cancer Prevention Research.

[49]  S. Kalloger,et al.  Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. , 2010, American journal of clinical pathology.

[50]  A. Skubitz,et al.  Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients , 2010, Journal of ovarian research.

[51]  Richard G. Moore,et al.  Current clinical use of biomarkers for epithelial ovarian cancer , 2010, Current opinion in oncology.

[52]  A. Skubitz,et al.  Quantitative proteomic analysis by iTRAQ® for the identification of candidate biomarkers in ovarian cancer serum , 2010, Proteome Science.

[53]  G. Rice,et al.  Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer , 2010, Journal of experimental & clinical cancer research : CR.

[54]  J. Marks,et al.  Development of a multimarker assay for early detection of ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[56]  A. Skubitz,et al.  Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in‐gel electrophoresis , 2010, Electrophoresis.

[57]  C. Bokemeyer,et al.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients , 2008, British Journal of Cancer.

[58]  Feng Su,et al.  The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? , 2008, American journal of obstetrics and gynecology.

[59]  yang-xin fu,et al.  Targeting tumors with LIGHT to generate metastasis-clearing immunity. , 2008, Cytokine & growth factor reviews.

[60]  Albert C Koong,et al.  Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. , 2008, Clinical chemistry.

[61]  Daniel W Chan,et al.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. , 2007, Gynecologic oncology.

[62]  E. Diamandis,et al.  Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma , 2007, Clinical Cancer Research.

[63]  A. Godwin,et al.  Increased Expression of the Pro-Protein Convertase Furin Predicts Decreased Survival in Ovarian Cancer , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[64]  A. Skubitz,et al.  Differential gene expression identifies subgroups of ovarian carcinoma. , 2006, Translational research : the journal of laboratory and clinical medicine.

[65]  A. Ullrich,et al.  ErbB-3 predicts survival in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Liz Y. Han,et al.  Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  B. Rosen,et al.  Who should operate on patients with ovarian cancer? An evidence-based review. , 2005, Gynecologic oncology.

[68]  David Chia,et al.  Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. , 2005, American journal of obstetrics and gynecology.

[69]  Kym Faull,et al.  Characterization of serum biomarkers for detection of early stage ovarian cancer , 2005, Proteomics.

[70]  K A Baggerly,et al.  New tumor markers: CA125 and beyond , 2005, International Journal of Gynecologic Cancer.

[71]  Christopher P Crum,et al.  Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. , 2005, Cancer research.

[72]  Robert Tibshirani,et al.  The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.

[73]  D. Fishman,et al.  Soluble Epidermal Growth Factor Receptor (SEG-FR) and Cancer Antigen 125 (CA125) as Screening and Diagnostic Tests for Epithelial Ovarian Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[74]  S. Skates,et al.  Blood and Urine Markers for Ovarian Cancer: A Comprehensive Review , 2004, Disease markers.

[75]  R. Bast,et al.  Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer , 2004, Cancer Research.

[76]  Amy P N Skubitz,et al.  Differential gene expression in ovarian carcinoma: identification of potential biomarkers. , 2004, The American journal of pathology.

[77]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[78]  Usha Menon,et al.  Progress and Challenges in Screening for Early Detection of Ovarian Cancer* , 2004, Molecular & Cellular Proteomics.

[79]  Michèl Schummer,et al.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. , 2003, Cancer research.

[80]  U. Menon.  Ovarian Cancer Screening in the General Population , 2003, Current opinion in obstetrics & gynecology.

[81]  D. Katsaros,et al.  Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[83]  D. Fishman,et al.  Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[84]  R. Berkowitz,et al.  Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. , 2001, Journal of the National Cancer Institute.

[85]  J. Smyth,et al.  Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.

[86]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[87]  U. Matulonis,et al.  Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[88]  H. Yazici,et al.  Utility of c-crbB-2 Expression in Tissue and Sera of Ovarian Cancer Patients , 2000, Cancer investigation.

[89]  T. Muramatsu,et al.  Expression of Midkine and Pleiotropin in Ovarian Tumors , 1997, Obstetrics and gynecology.

[90]  C. Kainz,et al.  Serum evaluation of interleukin 6 in ovarian cancer patients. , 1997, Gynecologic oncology.

[91]  Roderic D. M. Page,et al.  TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..

[92]  A. Gadducci,et al.  Preoperative serum intercellular adhesion molecule-1 (ICAM-1) and E-selectin (endothelial cell leukocyte adhesion molecule, ELAM-1) in patients with epithelial ovarian cancer. , 1995, Anticancer research.

[93]  R. Tibshirani,et al.  An Introduction to the Bootstrap , 1995 .

[94]  C. Peschle,et al.  Interleukin‐6 serum levels in patients with gynecological tumors , 1994, International journal of cancer.

[95]  E. Nice,et al.  Mice with a null mutation of the TGFα gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation , 1993, Cell.

[96]  J. Berek,et al.  Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[97]  A. García-de la Torre,et al.  Cancer antigens 19.9 and 125 as tumor markers in patients with mucinous ovarian tumors. , 2016, European journal of gynaecological oncology.

[98]  J. Sikora,et al.  Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors. , 2013, Human immunology.

[99]  J. Thigpen.  Effect of Screening on Ovarian Cancer Mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial , 2011 .

[100]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[101]  D. Fishman,et al.  Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[102]  Terukazu Nakamura,et al.  Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. , 2002, Cancer research.

[103]  B. Sheu,et al.  T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies. , 1999, Journal of the Formosan Medical Association = Taiwan yi zhi.

[104]  A. Schauer,et al.  Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. , 1997, Anticancer research.

[105]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .